Bristol-Myers Squibb's strong profitability, significant drug growth, and low valuation provide great upside potential. Read ...

In today's big story, we're closing in on the final stretch of President Donald Trump's first 100 days of his second term. So far, his most formidable opponent hasn't been Congress or the courts. It's ...